Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Desconocido
Fase 3
ClinicalTrials.gov
TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS
INTERVENTIONAL
Inicio: 1 de ene de 1990
ID: NCT00002499
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible
INTERVENTIONAL
Inicio: 5 de feb de 2020
ID: NCT04209114
Terminado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
INTERVENTIONAL
Inicio: 1 de abr de 2012
ID: NCT01528345
Completado
Fase 2
ClinicalTrials.gov
A Phase 1 and 2 Clinical Trial of ALIMTA® (Pemetrexed) in Combination With Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
INTERVENTIONAL
Inicio: 1 de jul de 2005
ID: NCT00489359
Completado
Fase 2
ClinicalTrials.gov
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
INTERVENTIONAL
Inicio: 1 de mar de 2016
ID: NCT02724540
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
INTERVENTIONAL
Inicio: 25 de jul de 2022
ID: NCT05382286
Completado
Fase 4
ClinicalTrials.gov
A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)
INTERVENTIONAL
Inicio: 1 de dic de 2006
ID: NCT00420927
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy
INTERVENTIONAL
Inicio: 1 de ago de 2003
ID: NCT00065325
Terminado
Fase 2
ClinicalTrials.gov
Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma
INTERVENTIONAL
Inicio: 7 de dic de 2021
ID: NCT05179603
Completado
ClinicalTrials.gov
Prevalence of Homologous Recombination Repair (HRR) Gene Mutations in Patients With Metastatic Castration-resistant Prostate Cancer in Latin America: PROSPECT Study.
OBSERVATIONAL
Inicio: 21 de abr de 2021
ID: NCT04962880
Completado
Fase 3
ClinicalTrials.gov
RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer
INTERVENTIONAL
Inicio: 30 de sept de 2019
ID: NCT03362177
Completado
Fase 1
ClinicalTrials.gov
A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
INTERVENTIONAL
Inicio: 17 de ago de 2022
ID: NCT05487235
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma
INTERVENTIONAL
Inicio: 2 de nov de 2023
ID: NCT06054555
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
INTERVENTIONAL
Inicio: 3 de mar de 2022
ID: NCT05064358
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
INTERVENTIONAL
Inicio: 22 de jul de 2022
ID: NCT05254743
Completado
Fase 3
ClinicalTrials.gov
A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer
INTERVENTIONAL
Inicio: 1 de nov de 1998
ID: NCT00241449
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
INTERVENTIONAL
Inicio: 22 de jun de 2023
ID: NCT05827016
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 18 de jul de 2022
ID: NCT05296798
Completado
ClinicalTrials.gov
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
OBSERVATIONAL
Inicio: 20 de ago de 2014
ID: NCT02141438
Por invitación
ClinicalTrials.gov
Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients
OBSERVATIONAL
Inicio: 1 de ago de 2024
ID: NCT06447532
Anterior
1
...
57
58
59
...
434
Siguiente
Filtros